Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Dmytro Hamov"'
Publikováno v:
Cureus. 14(6)
Significant progress has been achieved in treating patients with onco-hematological diseases, including chronic myeloid leukemia (CML). This is primarily associated with the development of targeted therapy involving tyrosine kinase inhibitors (TKIs),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2285be69d1e78a27cb83f1d9f00f4ea3
https://pubmed.ncbi.nlm.nih.gov/35812557
https://pubmed.ncbi.nlm.nih.gov/35812557
Publikováno v:
Cureus
The tyrosine kinase inhibitor (TKI) imatinib in rare cases can cause acute toxic hepatitis, hepatic failure, and death. Currently, the choice of further chronic myeloid leukemia (CML) therapy in patients after acute hepatotoxicity is still a difficul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cde0e7962f4f59f1098e713857a3028e
https://doi.org/10.7759/cureus.4411
https://doi.org/10.7759/cureus.4411
Autor:
Larysa Zhuravlyova, Iryna Dyagil, Iryna Dmytrenko, Dmytro Lopin, Kuznetsov Igor, Nataliia Lopina, Dmytro Hamov
Publikováno v:
Cureus
The introduction of imatinib has substantially changed the approaches to the therapy of chronic myeloid leukemia. However, this drug can cause hepatic failure and death in rare cases. This report describes a clinical case of acute, toxic imatinib-ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cefa7944fa7cc39911c635e193a1b5b
http://europepmc.org/articles/PMC6188217
http://europepmc.org/articles/PMC6188217